Rovadicitinib
- Generic Name
- Rovadicitinib
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Phase 3
Recruiting
- Conditions
- Graft-versus-host Disease
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT06682169
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06598956
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital), Jinan, Shandong, China
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04339400
- Locations
- 🇨🇳
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳West China Hospital ,Sichuan University, Chendu, Sichuan, China
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04326348
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath